1. The potential of multi-compound nanoparticles to bypass drug resistance in cancer

   • C. G. Da Silva
   • Godefridus J. Peters
   • Luis J. Cruz

   Review Article Open access 08 September 2017 Pages: 881 - 894

   

2. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

   • Bryan Oronsky
   • Scott Caroen
   • Corey A. Carter

   Review Article Open access 20 July 2017 Pages: 895 - 907

   

3. Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy

   • Xingjuan Shi
   • Xiaoou Sun

   Review Article 24 July 2017 Pages: 909 - 917

   

4. Animals living in polluted environments are a potential source of anti-tumor molecule(s)

   • Shareni Jeyamogan
   • Naveed Ahmed Khan
   • Ruqaiyyah Siddiqui

   Review Article 09 August 2017 Pages: 919 - 924

5. Repositioning of proton pump inhibitors in cancer therapy

   • Zhen-Ning Lu
   • Bing Tian
   • Xiu-Li Guo

   Review Article 31 August 2017 Pages: 925 - 937

   

6. Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107

   • Kei Sato
   • Chikara Kunisaki
   • Itaru Endo

   Original Article 14 September 2017 Pages: 939 - 943

   

7. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment

   • Kyung Kim
   • Reena Jha
   • Aiwu Ruth He

   Original Article 20 September 2017 Pages: 945 - 954

   

8. A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)

   • Yasuyuki Ikezawa
   • Hajime Asahina
   • on behalf of Hokkaido Lung Cancer Clinical Study Group

   Original Article 13 September 2017 Pages: 955 - 963

   

9. Innovative intraoral cooling device better tolerated and equally effective as ice cooling

   • Java Walladbegi
   • Martin Gellerstedt
   • Mats Jontell

   Original Article Open access 03 October 2017 Pages: 965 - 972

   

10. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1

    • Haifeng Zhang
    • Baoli Hu
    • Li Li

    Original Article 27 September 2017 Pages: 973 - 984

    

11. Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics

    • Roberto Pariente
    • Ignacio Bejarano
    • José A. Pariente

    Original Article 27 September 2017 Pages: 985 - 998

    

12. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab

    • Motoo Nomura
    • Atsushi Otsuka
    • Manabu Muto

    Original Article 05 October 2017 Pages: 999 - 1004

13. Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer

    • Panagiotis Samaras
    • Marina Tusup
    • Steve Pascolo

    Original Article 04 October 2017 Pages: 1005 - 1012

    

14. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification

    • Daniel Moj
    • Hannah Britz
    • Thorsten Lehr

    Original Article 07 October 2017 Pages: 1013 - 1026

    

15. Inhibitory growth evaluation and apoptosis induction in MCF-7 cancer cells by new 5-aryl-2-butylthio-1,3,4-oxadiazole derivatives

    • Rashmin Khanam
    • Kamal Ahmad
    • Fareeda Athar

    Short Communication 16 August 2017 Pages: 1027 - 1042

    

16. Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma

    • Zhengqiu Zhou
    • Tracy A. Howard
    • John L. Villano

    Short Communication 08 August 2017 Pages: 1043 - 1046